Literature DB >> 25125205

Hypothermia and operative mortality during on-pump coronary artery bypass grafting.

Kevin L Greason1, Sunghee Kim2, Rakesh M Suri3, Amelia S Wallace2, Brian R Englum2.   

Abstract

OBJECTIVE: Controversy surrounds the effect of hypothermia on operative mortality during cardiac surgery. The present study accessed a large clinical database of coronary artery bypass graft operations to address the issue.
METHODS: A retrospective review of the Society of Thoracic Surgeons Adult Cardiac Surgery Database identified patients treated with isolated, nonemergency, on-pump coronary artery bypass grafting from July 2011 to December 2012. The patients were divided into 3 groups according to their lowest core temperature during the procedure: moderate hypothermia (≤ 34 °C), mild hypothermia (>34 °C but ≤ 36 °C), and normothermia (>36 °C). The primary endpoint of the study was operative mortality, defined according to the Database criteria.
RESULTS: During the study period, 142,541 patients were available for analysis; 94,777 (66.5%) received moderate hypothermia, 42,750 (30.3%) mild hypothermia, and 5014 (3.5%) normothermia. Operative mortality occurred in 1394 patients (1.5%) in the moderate hypothermia, 534 (1.3%) in the mild hypothermia, and 105 (2.1%) in the normothermia group. Multivariate analysis identified hypothermia (both mild [odds ratio, 0.66; 95% confidence interval, 0.54-0.81; P < .0001] and moderate [odds ratio, 0.73; 95% confidence interval, 0.60-0.89; P = .0015]) was protective against operative mortality compared with normothermia. No incremental benefit was noted between the different hypothermia grades (P = .0827).
CONCLUSIONS: Most patients receive hypothermia during on-pump coronary artery bypass grafting. Hypothermia is protective against operative mortality compared with normothermia in such patients. Moderate hypothermia does not provide additional survival benefit.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25125205      PMCID: PMC4336164          DOI: 10.1016/j.jtcvs.2014.05.091

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

Review 1.  Benefits and risks of maintaining normothermia during cardiopulmonary bypass in adult cardiac surgery: a systematic review.

Authors:  Kwok M Ho; Jen Aik Tan
Journal:  Cardiovasc Ther       Date:  2009-12-23       Impact factor: 3.023

2.  Con: Cardiac surgery should be performed under warm conditions.

Authors:  Prakash A Patel; Nimesh D Desai
Journal:  J Cardiothorac Vasc Anesth       Date:  2012-07-11       Impact factor: 2.628

Review 3.  Pro: hypothermic cardiopulmonary bypass should be used routinely.

Authors:  Philip E F Roman; Alina M Grigore
Journal:  J Cardiothorac Vasc Anesth       Date:  2012-07-11       Impact factor: 2.628

4.  Randomised trial of normothermic versus hypothermic coronary bypass surgery. The Warm Heart Investigators.

Authors: 
Journal:  Lancet       Date:  1994-03-05       Impact factor: 79.321

5.  A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich.

Authors:  P A Mackowiak; S S Wasserman; M M Levine
Journal:  JAMA       Date:  1992 Sep 23-30       Impact factor: 56.272

6.  The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery.

Authors:  David M Shahian; Sean M O'Brien; Giovanni Filardo; Victor A Ferraris; Constance K Haan; Jeffrey B Rich; Sharon-Lise T Normand; Elizabeth R DeLong; Cynthia M Shewan; Rachel S Dokholyan; Eric D Peterson; Fred H Edwards; Richard P Anderson
Journal:  Ann Thorac Surg       Date:  2009-07       Impact factor: 4.330

  6 in total
  1 in total

1.  Analysis of intra-operative variables as predictors of 30-day readmission in patients undergoing glioma surgery at a single center.

Authors:  Iahn Cajigas; Anil K Mahavadi; Ashish H Shah; Veronica Borowy; Nathalie Abitbol; Michael E Ivan; Ricardo J Komotar; Richard H Epstein
Journal:  J Neurooncol       Date:  2019-10-22       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.